News

Filter

Current filters:

DiovanFemaraFinancial

Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes

26-01-2010

Swiss drugmaker Novartis this morning said that it had achieved record results in 2009 as momentum from…

AfinitorAlconAliskiren TabletsAmlodipine and ValsartanAstraZenecaCanakinumab InjectionDeferasiroxDiovanEuropeeverolimusExelonExelon PatchExforgeExjadeFemaraFinancialGleevecIlarisImatinib MesylateLansoprazoleLetrozoleLucentisNovartisOctreotide AcetatePharmaceuticalPrevacidPrevacid NapraPACRanibizumab InjectionReclastRivastigmine TartrateRivastigmine Transdermal SystemSandostatinSandozTekturnavalsartanzoledronic acidZoledronic Acid InjectionZometa

Novartis delivers strong new product momentum; raises full-year 2009 guidance

22-10-2009

Swiss drug major Novartis reported third-quarter 2009 results with 3% growth in group net sales to $11.1…

AfinitorAlconAmlodipine and ValsartanCanakinumab InjectionDeferasiroxDiovaneverolimusExforgeExjadeFemaraFinancialGleevecIlarisImatinib MesylateLetrozoleLucentisNovartisNystatinOctreotide AcetateOralPharmaceuticalRanibizumab InjectionReclastSandostatinSandozvalsartanzoledronic acidZoledronic Acid InjectionZometa

COMPANY SPOTLIGHT

Menarini

Back to top